STOCK TITAN

SRTS President & General Counsel reports new 1,000-share stock buy

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Sensus Healthcare, Inc. (SRTS) director and officer Michael Sardano reported a personal purchase of company stock. On 11/18/2025, he acquired 1,000 shares of common stock at a price of $3.80 per share, coded as a purchase transaction. Following this trade, he now beneficially owns 118,839 shares of Sensus Healthcare common stock with direct ownership.

Sardano is listed as a Director and as an Officer with the title President and General Counsel, indicating both governance and executive responsibilities at the company. This filing is made on Form 4, which reports changes in ownership of the company’s equity securities by insiders.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sardano Michael

(Last) (First) (Middle)
851 BROKEN SOUND PARKWAY NW
STE. 215

(Street)
BOCA RATON FL 33487

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Sensus Healthcare, Inc. [ SRTS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND GENERAL COUNSEL
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/18/2025 P 1,000 A $3.8 118,839 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Michael Sardano 11/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Sensus Healthcare (SRTS) report on this Form 4?

The Form 4 reports that Michael Sardano acquired 1,000 shares of Sensus Healthcare common stock on 11/18/2025 at a price of $3.80 per share.

Who is the reporting person in this Sensus Healthcare (SRTS) Form 4 filing?

The reporting person is Michael Sardano, who is identified as both a Director and an Officer of Sensus Healthcare, holding the title President and General Counsel.

How many Sensus Healthcare (SRTS) shares does Michael Sardano own after the reported transaction?

After the reported transaction, Michael Sardano beneficially owns 118,839 shares of Sensus Healthcare common stock with direct ownership.

What was the transaction code used in this Sensus Healthcare (SRTS) Form 4?

The transaction is coded as P in the Form 4, indicating a purchase of common stock.

Does this Sensus Healthcare (SRTS) Form 4 include any derivative securities transactions?

The provided excerpt shows no derivative securities reported in Table II, only a purchase of common stock in Table I.

Is the ownership reported by Michael Sardano in Sensus Healthcare (SRTS) direct or indirect?

The Form 4 indicates that the 118,839 shares of Sensus Healthcare common stock are held with direct (D) ownership.

Sensus Healthcare Inc

NASDAQ:SRTS

SRTS Rankings

SRTS Latest News

SRTS Latest SEC Filings

SRTS Stock Data

81.47M
13.43M
16.98%
29.25%
5.03%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
BOCA RATON